Format

Send to

Choose Destination
Open Rheumatol J. 2014 Oct 17;8:77-81. doi: 10.2174/1874312901408010077. eCollection 2014.

A new curcuma extract (flexofytol®) in osteoarthritis: results from a belgian real-life experience.

Author information

1
University of Brussels, Belgium.
2
Liège University Hospital, Belgium.
3
Liège University, Belgium.

Abstract

This retrospective observational study summarizes the experiences of 820 patients treated with a new Curcuma extract (Flexofytol®, 4-6 capsules per day), for more than 6 months for various forms of painful osteoarthritis. These experiences were reported by 110 Belgian general practitioners via a questionnaire that included quality-of-life parameters for assessing patient experience. Data were submitted to an independent statistician for analysis. Within the first 6 weeks, Flexofytol® improved patient pain, articular mobility, and quality of life. Excellent tolerance was reported, and more than half of these patients were able to discontinue analgaesic and anti-inflammatory drugs. Patient satisfaction was confirmed by their decision to maintain Flexofytol® therapy for more than 6 months. These data must be confirmed with randomized controlled studies. We currently conclude that Flexofytol® which is based on a new preparation of curcumin, is as a potential neutraceutical for the care of patients complaining of joint problems, with excellent tolerance and rapid benefits for articular mobility, pain, and quality of life.

KEYWORDS:

Curcumin; osteoarthritis; real life experience.

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center